A State-of-Art on Pharmaceutical Industry in India (2010–2020)
| Vol-6 | Issue-04 | April-2021 | Published Online: 15 April 2021 PDF | ||
| DOI: https://doi.org/10.31305/rrijm.2021.v06.i04.029 | ||
| Author(s) | ||
| Sandip Kumar Mukherjee 1; Dr. Deepak Verma 2 | ||
|
1Department of Business Management, Chaudhary Charan Singh University, Meerut, Uttar Pradesh, India 2Department of Business Management, Chaudhary Charan Singh University, Meerut, Uttar Pradesh, India |
||
| Abstract | ||
This review surveys the evolution of the Indian pharmaceutical industry from 2010 to 2020. It summarizes market growth, manufacturing and export trends, regulatory and intellectual property developments, pricing controls, active pharmaceutical ingredient (API) supply-chain dynamics (notably dependence on China), innovation and R&D patterns, the role of mergers & acquisitions and foreign direct investment (FDI), and the sector’s response to the early stages of the COVID-19 pandemic in 2020. The paper synthesizes government reports, academic studies and industry analyses to identify structural strengths, major challenges and policy implications for resilient future growth. |
||
| Keywords | ||
| Indian pharmaceutical industry; generics; APIs; DPCO; NPPA; patents; supply chain; 2010–2020 | ||
|
Statistics
Article View: 149
|
||
